Thirty-seven patients with thyroid cancer were treated at 1a Clinica Chirurgica of Parma between 1962 and 1970. Fourty-five per cent of tumors were papillary, 24 per cent follicular, 2 per cent medullary, 9 per cent anaplastic. Surgery combined with ormonal therapy formed the commonest treatment. Eighty-five per cent of the patients with papillary carcinoma 70 per cent with follicular and 33,3 per cent with anaplastic carcinoma survived for 10 years. This present series indicates that total thiroidectomy combined with ormonal therapy influences the survival time, confirms the prognostic value of histology and shows that papillary node metastases do not prejudice survival.

Download full-text PDF

Source

Publication Analysis

Top Keywords

cent follicular
8
cent anaplastic
8
combined ormonal
8
ormonal therapy
8
cent
7
[treatment thyroid
4
thyroid neoplasms
4
neoplasms proposed
4
proposed therapeutic
4
therapeutic plan]
4

Similar Publications

Recent advances in immunology have challenged the conventional division of T-lymphocyte function by uncovering novel subpopulations with diverse roles and characteristics. This article reviews these discoveries and their implications for understanding immune regulation and disease pathogenesis. Innovative techniques have enabled the identification of previously unrecognized T-lymphocyte subsets, disrupting the classical classification system.

View Article and Find Full Text PDF
Article Synopsis
  • Crohn's disease (CD) is linked to an increased risk of cancer, partly due to disease characteristics and immunosuppressive treatment; this study focuses on data from a northern Indian cohort to shed light on CD-related malignancies in Asia.
  • A total of 952 participants, with a mean age of 36.9 years and a follow-up period of 34 months, were analyzed, revealing a malignancy occurrence rate of 1.05%, which is 10.45 times higher than the general population.
  • By 30 years of diagnosis, the cumulative cancer risk for Indian individuals with CD was found to be 13.4%, covering various types of malignancies including bowel and extraintestinal cancers, but no cases of
View Article and Find Full Text PDF

Background:  Skull metastases from follicular thyroid carcinoma (FTC) are infrequent but clinically significant, often presenting with localized pain, neurologic deficits, and cranial nerve dysfunction. Early detection and accurate diagnosis pose challenges due to their asymptomatic nature in some cases.

Methods:  A systematic literature review, conducted following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, identified and analyzed 15 relevant studies focusing on large skull metastases in FTC.

View Article and Find Full Text PDF

Quantum Sensing of Free Radicals in Primary Human Granulosa Cells with Nanoscale Resolution.

ACS Cent Sci

September 2023

Department of Biomedical Engineering, Groningen University, University Medical Center Groningen, Antonius Deusinglaan 1, 9713 AW Groningen, The Netherlands.

Cumulus granulosa cells (cGCs) and mural granulosa cells (mGCs), although derived from the same precursors, are anatomically and functionally heterogeneous. They are critical for female fertility by supporting oocyte competence and follicular development. There are various techniques used to investigate the role of free radicals in mGCs and cCGs.

View Article and Find Full Text PDF
Article Synopsis
  • * A total of 604 patients were included, with most having benign conditions like nodular goitre and Graves' disease, while a significant number were diagnosed with thyroid malignancies, predominantly papillary thyroid carcinoma.
  • * Key findings included a low early postoperative nerve injury rate (4.9%), a 0.7% rate of persistent nerve injury, and early hypoparathyroidism linked to certain conditions, underlining the importance of careful monitoring during surgery.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!